Literature DB >> 12615732

Coregulation of epidermal growth factor receptor/human epidermal growth factor receptor 2 (HER2) levels and locations: quantitative analysis of HER2 overexpression effects.

Bart S Hendriks1, Lee K Opresko, H Steven Wiley, Douglas Lauffenburger.   

Abstract

Elevated expression of human epidermal growth factor receptor 2 (HER2) is known to alter cell signaling and behavioral responses implicated in tumor progression. However, multiple diverse mechanisms may be involved in these overall effects, including signaling by HER2 itself, modulation of signaling by epidermal growth factor receptor (EGFR), and modification of trafficking dynamics for both EGFR and HER2. Because these processes are so tightly interrelated, the net effect of HER2 overexpression is difficult to reliably attribute to any single particular mechanism. To take an important first step toward dissecting the effects of HER2 overexpression on cell responses in terms of the various specific underlying mechanisms, we have developed and validated a quantitative model of the relevant trafficking processes. We then use our model for successful prediction of EGFR and HER2 level and location changes attributable to HER2 overexpression in 184A1 human mammary epithelial cells expressing a series of HER2 levels by retroviral infection. Model predictions are based on our independent experimental measurement of key trafficking parameters for both EGFR and HER2. In terms of trafficking processes, HER2 overexpression reduces the EGFR internalization rate constant and increases the fraction of EGFR recycled. Consequently, our model successfully predicts that HER2 increases the overall level of activated EGFR by both enhancing its recycling and reducing its internalization, but it increases activated EGFR localization at the cell surface almost solely by its reduction of internalization. Furthermore, the model also successfully predicts the effects of monoclonal antibody 2C4, which interferes with HER2/EGFR heterodimerization, on EGFR and HER2 levels and compartmental locations. We anticipate that this model should ultimately be useful in parsing the relative contributions of direct effects of HER2 via signaling vis-a-vis indirect effects of HER2 via modification of EGFR signaling.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12615732

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  60 in total

1.  Association with membrane protrusions makes ErbB2 an internalization-resistant receptor.

Authors:  Anette M Hommelgaard; Mads Lerdrup; Bo van Deurs
Journal:  Mol Biol Cell       Date:  2004-01-23       Impact factor: 4.138

2.  Conference report--protein kinase inhibitors in cancer treatment: mixing and matching? Highlights of the keystone symposium on protein kinases and cancer; February 24-29, 2004; Lake Tahoe, California.

Authors:  Kris Novak
Journal:  MedGenMed       Date:  2004-04-05

3.  Epirubicin-[Anti-HER2/neu] Synthesized with an Epirubicin-(C13-imino)-EMCS Analog: Anti-Neoplastic Activity against Chemotherapeutic-Resistant SKBr-3 Mammary Carcinoma in Combination with Organic Selenium.

Authors:  Cody P Coyne; Toni Jones; Andrzej Sygula; John Bailey; Lesya Pinchuk
Journal:  J Cancer Ther       Date:  2011-03

4.  Ligand accumulation in autocrine cell cultures.

Authors:  Michael I Monine; Alexander M Berezhkovskii; Elizabeth J Joslin; H Steven Wiley; Douglas A Lauffenburger; Stanislav Y Shvartsman
Journal:  Biophys J       Date:  2005-01-14       Impact factor: 4.033

5.  Multiple reaction monitoring for robust quantitative proteomic analysis of cellular signaling networks.

Authors:  Alejandro Wolf-Yadlin; Sampsa Hautaniemi; Douglas A Lauffenburger; Forest M White
Journal:  Proc Natl Acad Sci U S A       Date:  2007-03-26       Impact factor: 11.205

6.  Time-resolved fluorescence resonance energy transfer (TR-FRET) to analyze the disruption of EGFR/HER2 dimers: a new method to evaluate the efficiency of targeted therapy using monoclonal antibodies.

Authors:  Nadège Gaborit; Christel Larbouret; Julie Vallaghe; Frédéric Peyrusson; Caroline Bascoul-Mollevi; Evelyne Crapez; David Azria; Thierry Chardès; Marie-Alix Poul; Gérard Mathis; Hervé Bazin; André Pèlegrin
Journal:  J Biol Chem       Date:  2011-01-31       Impact factor: 5.157

7.  The signaling and transformation potency of the overexpressed HER2 protein is dependent on the normally-expressed EGFR.

Authors:  Xiangdong Zhou; Yehenew M Agazie
Journal:  Cell Signal       Date:  2011-09-03       Impact factor: 4.315

8.  Endocytosis and sorting of ErbB2 and the site of action of cancer therapeutics trastuzumab and geldanamycin.

Authors:  Cary D Austin; Ann M De Mazière; Paul I Pisacane; Suzanne M van Dijk; Charles Eigenbrot; Mark X Sliwkowski; Judith Klumperman; Richard H Scheller
Journal:  Mol Biol Cell       Date:  2004-09-22       Impact factor: 4.138

9.  HER-2-mediated endocytosis of magnetic nanospheres and the implications in cell targeting and particle magnetization.

Authors:  Shy Chyi Wuang; Koon Gee Neoh; En-Tang Kang; Daniel W Pack; Deborah E Leckband
Journal:  Biomaterials       Date:  2008-03-04       Impact factor: 12.479

10.  HER/ErbB receptor interactions and signaling patterns in human mammary epithelial cells.

Authors:  Yi Zhang; Lee Opresko; Harish Shankaran; William B Chrisler; H Steven Wiley; Haluk Resat
Journal:  BMC Cell Biol       Date:  2009-10-31       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.